When you consent to participate and are enrolled in a clinical trial at Can-Med, the research coordinator will work closely with you to start scheduling the required study visits and procedures.  
 
The first visit in a clinical trial is a “screening visit” which consists of a series of tests to ensure that you meet the very specific medical criteria specified in the study protocol.  The screening visit includes an in-depth review of your medical record to assess the history and severity of your condition, medications that you may be taking, other health conditions and your medical history.  It also normally includes blood or urine tests, a physical exam, other procedures and at times questionnaires.

If all of the parameters measured during the screening visit meet the protocol criteria, you are then scheduled to receive treatment.

Depending on the study, treatment may be the active medication, or it may be a placebo or inactive substance.  You will be advised of the design of the study and your chance of receiving active medication or a placebo during the consent process.  The day of treatment is normally called “Day 0” in a clinical trial protocol.
 
Following Day 0, you will be scheduled to come back to Can-Med or Dr. Pommerville’s office for a series of visits and assessments.  The number of assessments and visits vary depending on the study and are all described in the informed consent form.  
 
During the study you are encouraged to call and ask the research coordinator or Dr. Pommerville any questions that you may have or if you have any concerns.  Communication in between study visits is very important.  Ensure that you report any hospitalizations or health concerns to the research coordinator as soon as you can.
 
The research team at Can-Med is always accessible and able to assist you regarding any concerns regarding your participation in the study.